PHVS: מחיר למכירות Pharvaris Corp

The primary driver for Pharvaris N.V. (PHVS) will be the market launch of oral treatments for hereditary angioedema. The price-to-sales multiple visualizes investor expectations, where the value represents the current metric. Profit potential is linked to replacing injections with tablets for HAE patients. Furthermore, the focus on proprietary internal development makes the company an attractive acquisition target for corporate behemoths.

The implementation of AI and automated compound synthesis systems at Pharvaris N.V. (PHVS) is accelerating preclinical testing, directly impacting the potential of future cash flows. By analyzing the historical P/S chart, an investor assesses the market value of the business through the ratio of market capitalization to total revenue, where a stable trend confirms sales resilience, while sharp deviations signal overvaluation or hidden reporting risks.